Edition:
India

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

8.20USD
23 Apr 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$8.20
Open
$7.71
Day's High
$8.23
Day's Low
$7.70
Volume
39,829
Avg. Vol
117,614
52-wk High
$16.70
52-wk Low
$6.75

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Reports FY2018 Financial Results
Friday, 8 Mar 2019 

March 8 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES YEAR-END 2018 FINANCIAL RESULTS.ALDEYRA THERAPEUTICS INC - RESULTS FROM ALLEVIATE PHASE 3 CLINICAL TRIAL IN ALLERGIC CONJUNCTIVITIS EXPECTED IN EARLY 2019.ALDEYRA THERAPEUTICS INC - OPERATIONS EXPECTED TO BE FUNDED THROUGH 2020.ALDEYRA THERAPEUTICS INC - RENEW ADAPTIVE PHASE 3 CLINICAL TRIAL IN DRY EYE DISEASE EXPECTED TO BEGIN IN FIRST HALF OF 2019.ALDEYRA THERAPEUTICS INC - RESULTS FROM SOLACE PHASE 3 CLINICAL TRIAL IN NONINFECTIOUS ANTERIOR UVEITIS EXPECTED IN SECOND HALF OF 2019.ALDEYRA THERAPEUTICS INC - ADAPTIVE PHASE 3 CLINICAL TRIAL OF ADX-2191 IN PROLIFERATIVE VITREORETINOPATHY EXPECTED TO BEGIN IN SECOND HALF OF 2019.  Full Article

Aldeyra Therapeutics expands retinal disease pipeline with acquisition of Helio Vision
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS EXPANDS RETINAL DISEASE PIPELINE WITH ACQUISITION OF HELIO VISION.ALDEYRA THERAPEUTICS INC - INITIAL CLINICAL TRIAL RESULTS EXPECTED IN 2020.ALDEYRA THERAPEUTICS - ACQUIRED HELIO VISION FOR AN UPFRONT PAYMENT OF APPROXIMATELY $10 MILLION IN COMMON STOCK, SUBJECT TO A SIX-MONTH LOCK-UP PERIOD,.ALDEYRA THERAPEUTICS INC - ACQUISITION OF HELIO VISION AND NEAR-TERM DEVELOPMENT OF ADX-2191 HAS NO IMPACT ON CO'S PREVIOUS FINANCIAL GUIDANCE.ALDEYRA THERAPEUTICS INC - UNDER DEAL, UPFRONT PAYMENT ALSO HAS AN ADDITIONAL $2.5 MILLION PAYMENT IN COMMON STOCK TWO YEARS FROM DATE OF CLOSING.ALDEYRA THERAPEUTICS INC - ADAPTIVE PHASE 3 CLINICAL PROGRAM FOR ADX-2191 IN PVR IS EXPECTED TO INITIATE IN 2019, WITH RESULTS EXPECTED IN 2020.ALDEYRA THERAPEUTICS - UNDER TERMS, ELIOTT & OTHER CO-FOUNDERS OF HELIO VISION WILL CONTINUE TO WORK WITH ALDEYRA ON ADX-2191 AS CONSULTANTS.  Full Article

Aldeyra Therapeutics Says Repaid All Outstanding Indebtedness
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS - ON NOV 20, CO REPAID IN FULL ALL OUTSTANDING INDEBTEDNESS & TERMINATED ALL COMMITMENTS UNDER LOAN & SECURITY AGREEMENT.ALDEYRA THERAPEUTICS - DID NOT INCUR MATERIAL EARLY TERMINATION PENALTIES DUE TO REPAYMENT OF INDEBTEDNESS OR TERMINATION OF LOAN AGREEMENT.  Full Article

Aldeyra Therapeutics Inc Announces Public Offering Of Common Stock
Friday, 28 Sep 2018 

Sept 27 (Reuters) - :ALDEYRA THERAPEUTICS, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.25 MILLION COMMON SHARES PRICED AT $13.75PER SHARE.  Full Article

Aldeyra Therapeutics Announces Positive Results From Phase 2B Dry Eye Disease Clinical Trial
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 2B DRY EYE DISEASE CLINICAL TRIAL.ALDEYRA THERAPEUTICS INC - PIVOTAL CLINICAL TESTING EXPECTED TO BEGIN IN 2019 FOLLOWING DISCUSSION WITH REGULATORY AUTHORITIES.ALDEYRA THERAPEUTICS INC - STATISTICALLY SIGNIFICANT IMPROVEMENT ACROSS MULTIPLE SYMPTOM AND SIGN MEASURES.ALDEYRA THERAPEUTICS INC - EARLY ONSET AND BROAD RANGE OF ACTIVITY SUPPORTS DIFFERENTIATED PRODUCT PROFILE.ALDEYRA - CONSISTENT WITH PREVIOUS CLINICAL TRIALS, TOPICAL OCULAR REPROXALAP WAS WELL TOLERATED, AND REPORTED ADVERSE EVENTS WERE GENERALLY MILD.  Full Article

Aldeyra Therapeutics Appoints Joshua Reed As CFO
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS APPOINTS JOSHUA REED AS CHIEF FINANCIAL OFFICER.ALDEYRA THERAPEUTICS INC - APPOINTMENT OF JOSHUA REED AS CHIEF FINANCIAL OFFICER.ALDEYRA THERAPEUTICS INC - REED WILL SUCCEED STEPHEN TULIPANO, COMPANY'S OUTGOING CHIEF FINANCIAL OFFICER.  Full Article

Aldeyra Therapeutics Announces Q1 Loss Per Share $0.43
Tuesday, 15 May 2018 

May 15 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.43.Q1 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S.QTRLY BASIC AND DILUTED NET LOSS PER SHARE $0.43.  Full Article

Aldeyra Therapeutics Announces Year End 2017 Financial Results
Thursday, 29 Mar 2018 

March 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES YEAR END 2017 FINANCIAL RESULTS.ALDEYRA THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $42.9 MILLION AS OF DECEMBER 31, 2017.  Full Article

Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING.  Full Article

Aldeyra Therapeutics reports Q3 loss per share of $0.32
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.32.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.‍Cash, cash equivalents, and marketable securities were $47.9 million as of September 30, 2017​.  Full Article

Aldeyra's eye drug meets main goal in late-stage study, shares surge

Aldeyra Therapeutics Inc said on Tuesday its drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.